With the company having suggested prostate cancer could increase potential sales by 500 million to 1 billion Swiss francs a year ($467 million to $934 million), Deutsche Bank analysts said the setback meant 0.5 to 2 percent might need to be come off consensus sales estimates for Roche and 1 to 4 percent from core earnings. Oliver Kaemmerer, an analyst at WestLB, said he was likely to lower his 2014 sales forecast for Avastin of 9.8 billion francs to nearer 9 billion, given that ovarian cancer was the only new opportunity now left available. Avastin, which works by starving tumors of blood, is already used to treat colon, breast, lung and kidney cancers, and had 2009 annual global sales of 6.2 billion Swiss francs. It is a flagship product for Roche, the world's largest maker of cancer drugs, given its potential to expand in these markets and move into treating new types of cancer 
Share:  With the company having suggested prostate cancer could increase potential sales by 500 million to 1 billion Swiss francs a year ($467 million to $934 million), Deutsche Bank analysts said the setback meant 0.5 to 2 percent might need to be come off consensus sales estimates for <span class="company">Roche</span> and 1 to 4 percent from core earnings.<span class="sent"> <span class="analyst">Oliver Kaemmerer</span>, an analyst at WestLB, said he was likely to lower his 2014 sales forecast for Avastin of 9.8 billion francs to nearer 9 billion, given that ovarian cancer was the only new opportunity now left available.</span> Avastin, which works by starving tumors of blood, is already used to treat colon, breast, lung and kidney cancers, and had 2009 annual global sales of 6.2 billion Swiss francs. It is a flagship product for <span class="company">Roche</span>, the world's largest maker of cancer drugs, given its potential to expand in these markets and move into treating new types of cancer....With the company having suggested prostate cancer could increase potential sales by 500 million to 1 billion Swiss francs a year ($467 million to $934 million), Deutsche Bank analysts said the setback meant 0.5 to 2 percent might need to be come off consensus sales estimates for <span class="company">Roche</span> and 1 to 4 percent from core earnings.<span class="sent"> <span class="analyst">Oliver Kaemmerer</span>, an analyst at WestLB, said he was likely to lower his 2014 sales forecast for Avastin of 9.8 billion francs to nearer 9 billion, give Tweet this 

With the company having suggested prostate cancer could boost potential annual peak sales by between 500 million Swiss francs ($464.3 million) and 1 billion, Deutsche Bank analysts said the setback meant 0.5 to 2 percent might need to be come off consensus sales estimates for Roche and 1 to 4 percent from core earnings. Oliver Kaemmerer, an analyst at WestLB, said he was likely to revise down his 2014 sales forecast for Avastin of 9.8 billion francs to nearer 9 billion, given that ovarian cancer was the only new opportunity now left available. Avastin, which works by starving tumours of blood, is already used to treat colon, breast, lung and kidney cancers, and had 2009 annual global sales of 6.2 billion Swiss francs. It is seen as the flagship product for Roche, the world's largest maker of cancer drugs, given its potential to expand in these markets and move into treating new types of cancer 
Share:  With the company having suggested prostate cancer could boost potential annual peak sales by between 500 million Swiss francs ($464.3 million) and 1 billion, Deutsche Bank analysts said the setback meant 0.5 to 2 percent might need to be come off consensus sales estimates for <span class="company">Roche</span> and 1 to 4 percent from core earnings.<span class="sent"> <span class="analyst">Oliver Kaemmerer</span>, an analyst at WestLB, said he was likely to revise down his 2014 sales forecast for Avastin of 9.8 billion francs to nearer 9 billion, given that ovarian cancer was the only new opportunity now left available.</span> Avastin, which works by starving tumours of blood, is already used to treat colon, breast, lung and kidney cancers, and had 2009 annual global sales of 6.2 billion Swiss francs. It is seen as the flagship product for <span class="company">Roche</span>, the world's largest maker of cancer drugs, given its potential to expand in these markets and move into treating new types of cancer....With the company having suggested prostate cancer could boost potential annual peak sales by between 500 million Swiss francs ($464.3 million) and 1 billion, Deutsche Bank analysts said the setback meant 0.5 to 2 percent might need to be come off consensus sales estimates for <span class="company">Roche</span> and 1 to 4 percent from core earnings.<span class="sent"> <span class="analyst">Oliver Kaemmerer</span>, an analyst at WestLB, said he was likely to revise down his 2014 sales forecast for Avastin of 9.8 billion francs to nearer 9 billion, given that Tweet this 

All U.S utilities located around the LG&E frontiers are loaded with debt," WestLB analyst Peter Wirtz said. 
Share:  <span class="sent">All U.S utilities located around the <span class="company">LG&E</span> frontiers are loaded with debt," WestLB analyst <span class="analyst">Peter Wirtz</span> said.</span> Tweet this 

All U.S utilities located around the LG&E frontiers are loaded with debt," WestLB analyst Peter Wirtz said. 
Share:  <span class="sent">All U.S utilities located around the <span class="company">LG&E</span> frontiers are loaded with debt," WestLB analyst <span class="analyst">Peter Wirtz</span> said.</span> Tweet this 

Both parties lobbied Environment Minister Norbert Roettgen , a lawmaker with Merkel's Christian Democratic Union, to cut subsidies for rooftop and park systems by similar levels Solon, Solarworld The more favorable legislation for parks affects about 50 percent of Phoenix Solar's sales, 25 percent at Q Cells, as much as 15 percent at Solon SE and 5 percent at Solarworld AG , Schramm said Q Cells International, the park building unit of Q Cells, "will be better placed for the sale of their parks," Sebastian Zank , an analyst with WestLB AG in Dusseldorf, said in a phone interview The draft also scraps a 2014 phase out for subsidies for land based systems in current law, permitting new systems built after that date to qualify for subsidies The legislation envisages further changes to solar aid from 2011, adjusting subsidies according to cumulative solar capacity added 
Share:  Both parties lobbied Environment Minister Norbert Roettgen , a lawmaker with Merkel's Christian Democratic Union, to cut subsidies for rooftop and park systems by similar levels Solon, Solarworld The more favorable legislation for parks affects about 50 percent of Phoenix Solar's sales, 25 percent at <span class="company">Q Cells</span>, as much as 15 percent at Solon SE and 5 percent at Solarworld AG , Schramm said<span class="sent"> <span class="company">Q Cells</span> International, the park building unit of <span class="company">Q Cells</span>, "will be better placed for the sale of their parks," <span class="analyst">Sebastian Zank</span> , an analyst with WestLB AG in Dusseldorf, said in a phone interview</span> The draft also scraps a 2014 phase out for subsidies for land based systems in current law, permitting new systems built after that date to qualify for subsidies The legislation envisages further changes to solar aid from 2011, adjusting subsidies according to cumulative solar capacity added...Both parties lobbied Environment Minister Norbert Roettgen , a lawmaker with Merkel's Christian Democratic Union, to cut subsidies for rooftop and park systems by similar levels Solon, Solarworld The more favorable legislation for parks affects about 50 percent of Phoenix Solar's sales, 25 percent at <span class="company">Q Cells</span>, as much as 15 percent at Solon SE and 5 percent at Solarworld AG , Schramm said<span class="sent"> <span class="company">Q Cells</span> International, the park building unit of <span class="company">Q Cells</span>, "will be better p Tweet this 

The more favorable legislation for parks affects about 50 percent of Phoenix Solar's sales, 25 percent at Q Cells, as much as 15 percent at Solon SE and 5 percent at Solarworld AG, Schramm said Q Cells International, the park building unit of Q Cells, "will be better placed for the sale of their parks," Sebastian Zank, an analyst with WestLB AG in Dusseldorf, said in a phone interview The draft also scraps a 2014 phase out for subsidies for land based systems in current law, permitting new systems built after that date to qualify for subsidies The legislation envisages further changes to solar aid from 2011, adjusting subsidies according to cumulative solar capacity added 
Share:  The more favorable legislation for parks affects about 50 percent of Phoenix Solar's sales, 25 percent at <span class="company">Q Cells</span>, as much as 15 percent at Solon SE and 5 percent at Solarworld AG, Schramm said<span class="sent"> <span class="company">Q Cells</span> International, the park building unit of <span class="company">Q Cells</span>, "will be better placed for the sale of their parks," <span class="analyst">Sebastian Zank</span>, an analyst with WestLB AG in Dusseldorf, said in a phone interview</span> The draft also scraps a 2014 phase out for subsidies for land based systems in current law, permitting new systems built after that date to qualify for subsidies The legislation envisages further changes to solar aid from 2011, adjusting subsidies according to cumulative solar capacity added...The more favorable legislation for parks affects about 50 percent of Phoenix Solar's sales, 25 percent at <span class="company">Q Cells</span>, as much as 15 percent at Solon SE and 5 percent at Solarworld AG, Schramm said<span class="sent"> <span class="company">Q Cells</span> International, the park building unit of <span class="company">Q Cells</span>, "will be better placed for the sale of their parks," <span class="analyst">Sebastian Zank</span>, an analyst with WestLB AG in Dusseldorf, said in a phone interview</span> The draft also scraps a 2014 phase out for subsidies for land based systems in current law, permitting new systems built after that date to qualify for subsidies The le Tweet this 

"The bottom line looks good but on the underlying level it was slightly below estimates," said WestLB analyst Christoph Bossmann BONUS CONTROVERSY BNP Paribas is the first of France's top banks to post fourth quarter results with the sector still weighed down by writedowns on toxic assets, the debt woes of Greece and a political backlash against bankers' bonuses 
Share:  <span class="sent">"The bottom line looks good but on the underlying level it was slightly below estimates," said WestLB analyst <span class="analyst">Christoph Bossmann</span> BONUS CONTROVERSY <span class="company">BNP Paribas</span> is the first of France's top banks to post fourth quarter results with the sector still weighed down by writedowns on toxic assets, the debt woes of Greece and a political backlash against bankers' bonuses</span>...<span class="sent">"The bottom line looks good but on the underlying level it was slightly below estimates," said WestLB analyst <span class="analyst">Christoph Bossmann</span> BONUS CONTROVERSY <span class="company">BNP Paribas</span> is the first of France's top banks to post fourth quarter results with the sector still weighed down by writedowns on toxic assets, the debt woes of Greece and a political backlash against bankers' bonuses</span> Tweet this 

RWE AG plans to sell a stake in a coal fired power plant valued at as much as 80 million euros ($110 million) as Germany's second largest utility seeks to lower carbon emissions The utility plans to sell its 246 percent holding in the 508 megawatt power station in Rostock, Jana Hinz, a plant spokeswoman, said yesterday by phone Manfred Lang, a spokesman for Essen, Germany based RWE's power generation unit, declined to comment on the matter A stake that size in a 16 year old coal plant such as Rostock may fetch as much as 80 million euros, according to WestLB AG analyst Peter Wirtz 
Share:  <span class="company">RWE AG</span> plans to sell a stake in a coal fired power plant valued at as much as 80 million euros ($110 million) as Germany's second largest utility seeks to lower carbon emissions The utility plans to sell its 246 percent holding in the 508 megawatt power station in Rostock, Jana Hinz, a plant spokeswoman, said yesterday by phone Manfred Lang, a spokesman for Essen, Germany based RWE's power generation unit, declined to comment on the matter<span class="sent"> A stake that size in a 16 year old coal plant such as Rostock may fetch as much as 80 million euros, according to WestLB AG analyst <span class="analyst">Peter Wirtz</span></span>...<span class="company">RWE AG</span> plans to sell a stake in a coal fired power plant valued at as much as 80 million euros ($110 million) as Germany's second largest utility seeks to lower carbon emissions The utility plans to sell its 246 percent holding in the 508 megawatt power station in Rostock, Jana Hinz, a plant spokeswoman, said yesterday by phone Manfred Lang, a spokesman for Essen, Germany based RWE's power generation unit, declined to comment on the matter<span class="sent"> A stake that size in a 16 year old coal plant such as Rostock may fetch as much as 80 million euros, according to WestLB AG analyst <span class="analyst">Peter Wirtz</span></span>...The utility plans to sell its 246 percent holding in the 508 megawatt power station in Rostock, Jana Hinz, a plant spokeswoman, said yesterday by phone Manfred Lang, a spokesman for Essen, G Tweet this 

Stong demand from emerging markets helped Nokia to sell 127 million phones in the quarter, above all analysts forecasts S&P Equity Research upgraded Nokia stock to buy from hold "These are really mind blowing results," said analyst Thomas Langer from WestLB "However, I think there is definitely a risk one gets over excited — the challenges in the smartphone markets will become obvious to everybody, and we think the competition will intensify throughout the year," Langer said 
Share:  Stong demand from emerging markets helped <span class="company">Nokia</span> to sell 127 million phones in the quarter, above all analysts forecasts<span class="sent"> S&P Equity Research upgraded <span class="company">Nokia</span> stock to buy from hold "These are really mind blowing results," said analyst <span class="analyst">Thomas Langer</span> from WestLB</span> "However, I think there is definitely a risk one gets over excited — the challenges in the smartphone markets will become obvious to everybody, and we think the competition will intensify throughout the year," Langer said...Stong demand from emerging markets helped <span class="company">Nokia</span> to sell 127 million phones in the quarter, above all analysts forecasts<span class="sent"> S&P Equity Research upgraded <span class="company">Nokia</span> stock to buy from hold "These are really mind blowing results," said analyst <span class="analyst">Thomas Langer</span> from WestLB</span> "However, I think there is definitely a risk one gets over excited — the challenges in the smartphone markets will become obvious to everybody, and we think the competition will intensify throughout the year," Langer said Tweet this